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Abstract: Sphingolipids are major constituents of the cells with emerging roles in the regulation of cellular processes. Deregulation of
sphingolipid metabolism is reflected as various pathophysiological conditions including metabolic disorders and several forms of cancer. 
Ceramides, ceramide-1-phosphate (C1P), glucosyl ceramide (GluCer), sphingosine and sphingosine-1-phosphate (S1P) are among the 
bioactive sphingolipid species that have important roles in the regulation of cell death, survival and chemotherapeutic resistance. Some of 
those species are known to accumulate in the cells upon chemotherapy while some others are known to exhibit an opposite pattern. Even 
though the length of fatty acid chain has a deterministic effect, in general, upregulation of ceramides and sphingosine is known to induce 
apoptosis. However, S1P, C1P and GluCer are proliferative for cells and they are involved in the development of chemoresistance.
Therefore, sphingolipid metabolism appears as a good target for the development of novel therapeutics or supportive interventions to  
increase the effectiveness of the chemotherapeutic drugs currently in hand. Some approaches involve manipulation of the synthesis  
pathways yielding the increased production of apoptotic sphingolipids while the proliferative ones are suppressed. Some others are trying 
to take advantage of cytotoxic sphingolipids like short chain ceramide analogs by directly delivering them to the malignant cells as a  
distinct chemotherapeutic intervention. Numerous studies in the literature show the feasibility of those approaches especially in acute and 
chronic leukemias. This review compiles the current knowledge about sphingolipids and their roles in chemotherapeutic response with 
the particular attention to leukemias. 
Keywords: Ceramide, ceramide-1-phosphate, chemotherapeutic response, dihydroceramide, glucosylceramide, leukemia, sphingosine, 
sphingosine-1-phosphate. 
INTRODUCTION 
 Sphingolipids form a major class of lipids found within the 
eukaryotic membranes and an unusual class of bacterial genus 
called Sphingobacteria. General structure of sphingolipids contains 
a long-chain sphingosine base and an amide-linked fatty acid chain. 
These molecules have amphiphatic structures having polar and 
nonpolar parts like phospholipids. Various polar head groups and 
differing lengths of fatty acid chain produce a wide range of sphin-
golipids and give different characteristics to them. Following their 
discovery in late 1800s, versatile nature of sphingolipids appeared 
enigmatic to scientific community and for a long time, they were 
thought to be important solely for structural purposes in cells. Last 
decades have shown that they are not simple cellular building 
blocks; instead they are involved in several other processes includ-
ing but not limited to cell cycle control, apoptosis and differentia-
tion [1-3]. Sphingolipids are involved in the regulation of essential 
cellular processes by participating to signal transduction pathways 
as secondary messengers. 
 Studies pointing out the roles of sphingolipids in pathophysiol-
ogy of various diseases including cancer and metabolic disorders 
have increased the attention to lipid research lately and therapeutic 
interventions are started to incorporate approaches targeting sphin-
golipid synthesis pathways. By means of those efforts, numerous 
sphingolipid species with promising therapeutic importance are 
identified by manipulating their cellular levels. Ceramide (Cer), 
ceramide-1-phosphate (C1P), glucosylceramide (GluCer), dihydro-
ceramide (dhCer), sphingosine (Sph), and sphingosine-1-phosphate 
(S1P) are among those sphingolipid species that have important 
regulative roles in cells (for their chemical structures please see Fig. 1).
Some of those species play opposing roles while some others  
are working in concert for the similar outcome; and cellular fate is 
determined by their interactions and ratios in the cell [4-6]. 
 This review attempts to provide an overview of what is known 
for particular roles of such sphingolipids, and their implications in  
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cancer area. Roles of sphingolipids will be examined in the perspec-
tive of chemotherapeutic response with the emphasis on targeting 
these mechanisms for the treatment of leukemias. Towards the end, 
possibility of targeting sphingolipid metabolism as an alternative or 
a supportive therapeutic intervention will be discussed. 
METABOLISM OF SPHINGOLIPIDS 
 There are many inter-conversions among different sphingolipid 
species but one of them, ceramide, is particularly important as  
being located in the middle of this complex metabolic pathway. 
Therefore, ceramide is essential for the synthesis of other sphin-
golipids and back-reactions catalyzed by different enzymes contrib-
ute to the ceramide pool by converting other types of sphingolipids, 
indicating that this is not a one way process, instead, it has a  
dynamic nature [7-9]. Ceramide is formed by the addition of a fatty 
acid chain with varying number of carbon atoms to sphingosine 
base. There are multiple mechanisms responsible for ceramide  
production in cells. Ceramide can be produced from serine and 
palmitoyl CoA in endoplasmic reticulum (ER) via de novo synthesis 
(Fig. 2) [10, 11]. This pathway involves several chemical reactions 
and separate enzymes catalyzing each step. First condensation  
step is catalyzed by serine palmitoyltransferase producing 3-
ketosphinganine (3-ketodihydrosphingosine) [12]. In subsequent 
steps, 3-ketosphinganine is converted to sphinganine (dihy-
drosphingosine) that would in turn serve as a substrate for dihydro-
ceramide synthase (known as Lass or CerS) for acylation to dhCer 
[13, 14]. This step is reversible and the back-reaction is catalyzed 
by ceramidases (CDase). Desaturation of dhCer produces ceramide 
in the last step of de novo synthesis pathway (Fig. 1) [15, 16].  
Alternatively, ceramides can be synthesized from sphingomyelin by 
the catalysis of sphingomyelinase (SMase) [17, 18]. According to 
pH optima, SMases are named as acid SMase, neutral SMase, and 
alkaline SMase. Not surprisingly, these classes of enzymes have 
preference for subcellular localizations due to their optimal pH 
ranges. Moreover, generation of ceramides by different SMases is 
thought to attribute different functions to the ceramide products, 
which might have distinct and profound effects in signaling [19]. 
Reverse reaction is also possible by the catalysis of sphingomyelin 
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synthase producing sphingomyelin from ceramide with a process 
involving utilization of phosphatidylcholine and liberation of dia-
cylglycerol meanwhile [20]. This reaction specifically takes place 
in Golgi and ceramides that would be used for SM production are 
transported to this compartment by ceramide transfer protein, 
CERT [21]. As the last mechanism, degradation of complex sphin-
golipids can also result in the production of ceramides by a process 
called “salvage pathway” [22]. This pathway involves intermediates 
such as GluCer and galactosylceramide (GalCer) as the direct  
products of degradation; but they are hydrolyzed to ceramides by 
specific enzymes subsequently (Fig. 2) [23, 24]. 
 Sphingosine is synthesized from ceramides by CDases by the 
removal of amide-linked fatty acid chain. Similar to SMases, there 
are different types of CDases classified according to their optimal 
pH for enzymatic catalysis as acid CDases, neutral CDases and 
alkaline CDases [25-27]. In this mechanism, ceramides can also be 
derived from sphingosine by ceramide synthase (encoded by a fam-
ily of genes called Lass genes - longevity assurance homologue-1 
of yeast Lag1) in the reverse reaction. Upon its synthesis, sphingos-
ine can be modified to sphingosine-1-phosphate (S1P) by sphingos-
ine kinase (SphK) [28]. Sphingosine phosphatase can catalyze the 
reverse reaction by removing the phosphate group. S1P can be fur-
ther metabolized by S1P lyase yielding ethanolamine phosphate and 
hexadecanal. This is an irreversible step but products can be con-
verted into palmitate for re-utilization in the sphingolipid metabo-
lism (Fig. 2) [29]. 
 Glucosylceramide (GluCer) is synthesized from ceramides in 
Golgi by GluCer synthase (GCS) and it serves as a substrate for the 
synthesis of complex glycosphingolipids in the same subcellular 
compartment. Unlike CERT-mediated transport that is seen during 
SM production, ceramides are carried to Golgi by vesicles budding 
off directly from ER without the direct involvement of a protein 
transporter [30]. However, GluCer associates with some proteins 
for transport through Golgi in the subsequent reactions leading to 
the synthesis of complex glycosphingolipids [31, 32]. GluCer can 
be converted back to ceramide by glucosylceramidase [33]. How-
ever, ceramide is not limited to the biochemical conversions listed 
above. It can also undergo phosphorylation by the catalysis of ce-
ramide kinase [34] and this modification changes its characteristics 
and downstream targets profoundly as it will be discussed in the 
following section. 
CELLULAR ROLES OF BIOACTIVE SPHINGOLIPIDS 
 Accumulating body of evidence for decades suggests that bio-
active sphingolipids are involved in the regulation of many cellular 
processes. Deregulation of sphingolipid metabolism is implicated in 
several forms of metabolic disease and malignancies [35-37]. 
Moreover, different forms of sphingolipids exert distinct regulatory 
functions. Therefore, a delicate balance among lipid players needs 
to be maintained for homeostasis under varying environmental 
conditions [38-41]. 
Fig. (1). Chemical structures of various bioactive sphingolipids. Ceramide and its derivatives shown in this figure contain 16 carbon atoms in the fatty acid 
chain and hence named as C16-ceramides. 
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a). Ceramide Derivatives: Ceramide, C1P, GluCer, and dhCer 
 Ceramide is maybe the most intensely studied sphingolipid 
among the others. Therefore there is a wide array of data about the 
roles of ceramide in different physiological and pathophysiological 
conditions. One of the well known functions of ceramides is  
involvement in type-I programmed cell death, or apoptosis (this is 
not valid for every single type of ceramide; in fact fatty acid chain 
length has a deterministic effect on the behavior of the ceramide as 
more will be discussed about this below). In numerous different 
model systems, ceramides are shown to induce apoptosis with some 
overlapping and non-overlapping mechanisms. For instance, de novo
ceramide generation was found to be important for triggering apop-
tosis specifically in melanoma cells as evidenced by the lack of 
apoptosis when serine palmitoyltransferase activity is blocked [42]. 
However in prostate cancer cancer cell lines, ceramide-mediated 
apoptosis appeared to be driven by Akt dephosphorylation through 
protein phosphatase 2A activity [43]. Similarly, in another study, 
ceramide analogs were shown to induce apoptosis by affecting mi-
tochondria along with the concomitant dephosphorylation of Akt 
[44]. Supporting this mechanism, ceramide channels formed on the 
mitochondrial membranes were documented to be important for the 
release of pro-apoptotic factors to cytosol [45]. This finding was 
recapitulated by various other studies involving different model 
systems. Interestingly, a recent report has shown that mitochondri-
ally-targeted ceramide analog LCL29 is more potent for retarding 
cell growth in MCF7 breast cancer cell line through autophagy and 
apoptosis compared to uncharged ceramides suggesting that target-
ing ceramides to mitochondria might enhance the efficacy of the 
compound for therapeutic purposes [46]. In another report, upregu-
lation of ceramide correlated with the activation of proapoptotic 
genes; and apoptosis is inhibited by blocking the ceramide pathway 
in breast cancer cells indicating the importance of ceramides in the 
actual apoptotic induction [47]. Cytochrome C release is mediated 
directly by ceramides as shown in the isolated mitochondria [48]. 
Ceramide-mediated apoptosis is not only important for cancer cell 
death but also thought to be present in various healthy cells includ-
Fig. (2). Biochemical inter-conversions of sphingolipid species and compounds inhibiting or inducing the specific enzymes in this pathway. CerS (LASS), 
ceramide synthase; CDase, ceramidase; DES, dihydroceramide desaturase; SMS, sphingomyelin synthase; SMase, sphingomyelinase; GCS, glucosyl ceramide 
synthase; GCase, glucosyl ceramidase; CK, ceramide kinase; S1P, sphingosine-1-phosphate; SPPase, S1P phosphatase; SK, sphingosine kinase; C1PP, cera-
mide-1-phosphate phosphatase. T-9-X, tricyclodecan-9-yl-xanthogenate; LAQ824, histone deacetylase inhibitor; 4-HPR, N-(4-hydroxyphenyl) retinamide; 
ATRA, all-trans-retinoic acid; Ara-C, cytosine arabinoside; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoblastic 
leukemia; CML, chronic myeloid leukemia; APL, acute promyelocytic leukemia. 
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ing macrophages and developing embryos which suggests its im-
portance for maintaining homeostasis in healthy cells as well [49, 
50]. Furthermore, apoptotic induction by ceramides is a known 
mechanism for stress-induced cell death as shown by numerous 
studies [51-54]. As an example, conversion of sphingomyelin to 
ceramide was documented during apoptosis upon heat-stress [55]. 
A similar pathway is responsible for insulinoma cell death induced 
by ER-stress [56, 57]. However, there are some other studies indi-
cating that ceramides might be dispensable for cell death under 
certain stress conditions [54, 58] preventing us to generalize cera-
mide-mediated apoptosis as “the mechanism” for stress-induced 
cell death. Moreover, ceramides having long fatty acid chains be-
have somewhat differently in the regulation of cellular processes. 
While ceramides are generally known to exert growth suppressive 
and apoptotic functions, C16-ceramide was documented to be anti-
apoptotic and provide protection against cell death upon ER stress 
[59]. Similar observations were done in other models attributing 
anti-apoptotic roles to long chain ceramides [60, 61]. 
 C1P has opposing regulatory roles compared to ceramides. 
Unlike majority of ceramides, C1P is known to induce DNA repli-
cation, suppress apoptosis and favor survival of cells [62, 63].  
Protein kinase C- was shown to be essential for the proliferative 
effects of C1P [64]. In a study involving macrophages, suppression 
of apoptosis by C1P was shown to be taking place via inhibition  
of de novo ceramide synthesis pathway [65]. Nitric oxide (NO) is 
also thought to have roles in C1P-mediated survival as evidenced 
by the abrogation of pro-survival effects in the presence of inhibi-
tors for NO synthase [66]. In macrophages, C1P activates PI3 
kinase, JNK and ERK1/2 pathways to mediate pro-survival effects 
[67]. On the other hand, C1P analogs were documented to exert 
anti-inflammatory functions through suppression of TNF- and 
induction of IL-10 production in macrophages [68]. This role was 
confirmed by various other groups as well, attributing the impor-
tance to C1P in the regulation of inflammatory response [69-71]. 
Besides this, C1P is also thought to have roles in the regulation of 
intracellular Ca2+ levels [72-74]. 
 GluCer is another type of proliferative sphingolipids and it has 
roles in the development of chemotherapeutic resistance [75-77]. 
Multidrug transporter, P-glycoprotein (P-gp), was shown to potenti-
ate ceramide glycosylation, and addition of GCS inhibitors sensi-
tized cells to chemotherapy [78]. Chemoresistance conferred by 
GluCer is mediated by the inhibition of NADPH oxidase; hence 
augmenting NADPH oxidase activity provides sensitivity to chemo-
therapy [75]. GluCer was also shown to directly upregulate MDR1 
expression via cSrc and -catenin pathways producing chemoresis-
tant cancer subtypes [79]. In leukemic cell lines, GCS was found to 
contribute drug resistance by upregulating anti-apoptotic Bcl-2 
[80]. Upregulation of GCS correlates with poor prognosis and ag-
gressive nature of the neoplasm as shown by studies on different 
cancer models [81, 82]. GluCer is not only important for conferring 
chemotherapeutic resistance to cancer cells, but it is also important 
for the pathophysiology of several disorders including Gaucher 
disease, polycystic kidney disease and asthma [83-85]. Membrane 
trafficking, natural killer lymphocyte polarization and neuronal 
activation can be given as examples of other cellular processes 
involving GluCer [86-88]. 
 Dihydroceramide (dhCer) has several functions in cells some of 
which looks a bit controversial. By some groups dhCer was shown 
not to be important for inducing apoptosis and cell cycle arrest [89, 
90]. Opposite to those observations, in some other studies, a low 
but considerable level of apoptotic induction is linked to dhCer [91, 
92]. dhCer was shown to increase in response to 4-HPR chemother-
apy in ovarian cancers concomitantly with the increased levels of 
apoptosis by a process reversed by sphingosine kinase activity [25, 
93]. In another study, inhibition of dhCer synthesis correlated with 
reduced viability in T-cell leukemia line [94]. Ceramide-to-dhCer 
ratio was shown to be a determinant in the apoptotic decision in 
another report, possibly by modulating ceramide channels through 
conversion of ceramide to dhCer [95]. Loss of dhCer was correlated 
with rapid cell growth and increased apoptosis interestingly, and 
this phenotype was rescued with the activation of dhCer synthesis 
in some neurodegerative disorders [96]. Autophagy, self-destruc- 
tion of the cellular components, is another process in which dhCer 
is thought to have regulatory roles [97, 98]. In some studies it was 
documented that not the increased intracellular dhCer level; but the 
conversion of dhCer into other sphingolipids per se is responsible 
for some of the listed phenotypes above [99]. 
b). Sphingosine Derivatives: Sphingosine and S1P 
 Sphingosine is a growth suppressive and apoptotic sphingolipid, 
like ceramide. This feature of sphingosine is documented in several 
cell types including both malignant and healthy cells [100]. Leuke-
mic cells including multidrug resistant subtypes [101-103], various 
forms of carcinoma [104], and soft tissue sarcoma cells [105] were 
shown to undergo apoptosis upon exposure to sphingosine or in 
response to increased intracellular levels of sphingosine. Apoptotic 
induction mechanism of sphingosine was shown to be dependent on 
cytochrome c release from mitochondria in neurons and astrocytes 
[106]. In some other studies, sphingosine was found to exert its 
functions through the inhibition of protein kinase C [107]. This 
particular sphingolipid also has regulative functions for phagocyto-
sis as shown in alveolar macrophages [108]. In this study, conver-
sion of ceramides into sphingosine impaired clearance of apoptotic 
bodies by macrophages in a dose-dependent manner. 
 Sphingosine-1-phosphate (S1P) plays a totally different role in 
the regulation of cellular fate. It antagonizes ceramide and sphin-
gosine and favors cell survival. When endothelial cells are beamed 
with ionizing radiation, S1P was shown to activate AKT pathway to 
protect the cells from apoptosis [109]. Loss of sphingosine kinase 
activity was shown to increase the sensitivity to the DNA damaging 
chemotherapy with the concomitant increase in reactive oxygen 
species [110]. Blocking S1P production was shown to have possible 
implications in the suppression of angiogenesis which is an instru-
mental process for tumor growth [111, 112]. Other than its implica-
tions in cancer, S1P signaling was shown to be important in various 
other processes as well. For instance, recruitment of inflammatory 
macrophages in atherosclerosis appears to be mediated by S1P-
driven chemotaxis [113]. It is also known to be important for the 
migration of other cell types including myofibroblasts [114], osteo-
clast precursors [115] and hepatic stellate cells [116]. S1P signaling 
is also thought to be important in multiple sclerosis provided the 
drugs modulating S1P receptor activity could be used as good 
therapeutic options for the relapsing disease [117, 118]. Further-
more, S1P appears to be a promising target for the treatment of 
rheumatoid arthritis (as reviewed in [119]) and asthma [120]. Inter-
estingly, in a study of murine collagen-induced arthritis model, two 
isoenzymes responsible for the production of S1P (sphingosine 
kinase 1 and sphingosine kinase 2) were shown to have distinct 
cellular functions [121].This surprising finding was also confirmed 
by other groups in different models [122-124]. In one of those stud-
ies, SphK1 and SphK2 were shown to have opposing functions for 
the regulation of ceramide biosynthesis [124]. Unlike SphK1, 
SphK2 was found to be inhibitory for cell growth through calcium-
mediated apoptosis. Authors of this study argue that cellular loca-
tion of the S1P product is deterministic to its function as evidenced 
by anti-apoptotic to pro-apoptotic conversion of SphK1 upon  
targeting to ER.  
SPHINGOLIPIDS IN THE PERSPECTIVE OF CHEMO- 
THERAPEUTIC RESPONSE 
 As seen above, bioactive sphingolipids play important roles in 
the regulation of several cellular processes. Programmed cell death 
and the opposing activation of pro-survival mechanisms are among 
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those processes which are regulated by sphingolipids, at least in 
part. Therefore, not surprisingly, sphingolipids are implicated in the 
chemotherapeutic response of various anti-cancer agents on various 
types of malignancies. By numerous studies it was shown that  
accumulation of apoptotic sphingolipids such as ceramide and 
sphingosine is responsible for the cytotoxicity of the chemothera-
peutic agent in question. For instance, accumulation of ceramide 
was found to damage mitochondria and induce apoptosis in a 
caspase-independent manner upon curcumin treatment in prostate 
cancer cells [125]. Another study supported this observation by 
showing C6 ceramides contribute to sensitization to curcumin in 
melanoma cells [126]. Generation of ceramides was shown to reduce 
the viability of hormone-resistant prostate cancer cells upon treat-
ment with the cannabinoid R+ methanandamide as evidenced by 
the reversal of the cytotoxicity by the addition of ceramide synthase 
inhibitor Fumosin B1 [127]. In gastrointestinal tumors, combination 
of targeted therapeutics vorinostat and sorafenib upregulated CD95 
through ceramide signaling which in turn resulted in the increase of 
reactive oxygen species for killing the cancerous cells [128]. De 
novo pathway is suspected to be the important mechanism in this 
type of cytotoxicity as evidenced by the increased levels of dhCer 
which is the intermediate product of this pathway. A similar obser-
vation was done in ovarian cancer cells treated with synthetic reti-
noids [129]. In this study, mass spectrometry analysis identified 
more than 30 species of sphingolipids, dhCer species being in  
particular, increased upon drug treatment,. Etoposide induced  
apoptosis through increasing intracellular ceramides by activating 
serine palmitoyltransferase enzyme in Molt-4 human ALL cells 
[130]. Fludarabine induced apoptosis in WSU and JVM-2 CLL 
cells through inducing de novo ceramide generation and increasing 
sphingomyelinase enzyme activity [131]. Histone deacetylase  
inhibitor LAQ824 triggered apoptosis in U937 cells through  
ceramide generation by activating acid sphingomyelinase [132]. 
Tricyclodecan-9-yl-xanthogenate induced apoptosis in U937 cells 
in a time and dose-dependent manner by inhibiting SMS activity 
and increasing intracellular levels of ceramides [133]. Photody-
namic treatment resulted in a time-dependent ceramide accumula-
tion in U937 cells [134]. Sodium nitroprusside elevated ceramide 
levels through increasing the activity of neutral sphingomyelinase 
enzyme activity in acute promyelocytic leukemia cells [135].  
Ionizing radiation resulted in hydrolysis of SM and generation  
of ceramide through the activation of neutral sphingomyelinase in 
TF-1-33 AML cells [136]. Diphtheria toxin conjugated to granulocyte-
macrophage colony-stimulating factor (DT(388)-GM-CSF) elevated 
ceramide levels significantly and decreased the viability in vincris-
tine resistant HL60 cells. Similar results were obtained for parental 
sensitive counterparts [137]. Treatment of HL60 cells with cytosine 
arabinoside increased ceramide levels in a time- and dose-
dependent manner. Researchers detected these increases as early  
as 5 min after cytosine arabinoside exposure. On the other hand, 
cytosine arabinoside also activated neutral sphingomyelinase  
[138]. Forced expression of SK1 in LAMA84 CML cells inhibited 
imatinib-induced apoptosis while inhibition of SK1 with F-12509a 
or application of SK1 siRNA induced apoptosis in both parental 
sensitive and imatinib-resistant LAMA84 cells [139]. 
 In majority of the studies presented above and shown in Fig. 
(2), elevation of the apoptotic sphingolipids was found to be coinci-
dent with the chemotherapy, suggesting that these sphingolipids 
may be playing effector roles in those mechanisms. In agreement 
with this point of view, there are numerous other reports in which 
exogenous sphingolipids (short chain ceramides in particular) were 
provided to the cells and cancer eradication was obtained as well 
[140-142]. In fact, providing synthetic sphingolipids might have 
better outcomes for therapeutic purposes since availability and 
rapid metabolism of natural sphingolipids limit their utilization. 
FTY720 is a chemically synthesizable analog for sphingosine [143] 
which was shown to be effective for the treatment of CLL and 
CML [144, 145]. Mechanism of action is dependent on protein 
phosphatase 2A (PP2A) activation resulting in shutting down of the 
signaling pathways driving leukomogenesis [146-148]. While 
FTY720 is phosphorylated by sphingosine kinases (where SphK2 
has higher potential for this process) [149, 150]; VPC23019 is a 
synthetic compound analogous to S1P which directly antagonizes 
S1P(1) and S1P(2) receptors by competing with S1P [151]. How-
ever novel compounds are still being synthesized to enhance the 
solubility and in vivo efficacy of such antagonists [152]. These 
studies show that particular sphingolipid species can be used for 
obtaining better clearance of cancerous cells as distinct che-
motherapeutic options. Addressing the same issue, many other pa-
pers have shown that manipulating sphingolipid metabolism might 
have important applications for obtaining better responses to con-
ventional chemotherapy and for overcoming chemotherapeutic 
resistance developed by many tumors in the course of cancer pro-
gression. The main logic behind those studies can be summarized as 
suppressing the enzymes responsible for the production of growth-
promoting sphingolipids [153, 154] and/or activating enzymes re-
sponsible for the production of apoptotic ceramides and sphingos-
ine [155, 156]. Since efficacy of such an approach has been proven 
by several studies, it is currently a hot topic for developing new 
therapies to the variety of cancer types (as reviewed in [35, 157]). 
Short chain ceramides with apoptotic induction capabilities [158]; 
GluCer and S1P with undesired contribution to drug resistance and 
cancer cell survival [78, 79, 159] come forward as good targets for 
manipulation in this manner. Sphingolipids might play effector 
roles as seen in the numerous studies above; but they are also util-
ized for better drug delivery options. There are some studies indi-
cating that sphingolipid-conjugated nanoparticles are more effective 
in delivering the chemotherapeutic agent to cancer cells specifically 
[160, 161]. This approach was tested in various xenograft and syn-
geneic tumor models in mice and proven to be effective for better 
responses to chemotherapy [162, 163]. Taken together, gathered 
data attribute an important role to sphingolipid metabolism and its 
individual components for the development of effective therapeu-
tics and for overcoming drug resistance which is a major challenge 
in clinic for obtaining the desired response to the chemotherapeutic 
options in hand. 
TARGETING SPHINGOLIPID METABOLISM FOR THE 
TREATMENT OF LEUKEMIAS 
 Leukemia research is one of broadest areas in which targeted 
therapies are most advanced lately. The more we understand the 
characteristics of malignant transformation in blood-forming tis-
sues, the more we develop therapeutic options that work specifi-
cally on cancer cells and give the least damage to healthy cells in 
the body as possible. However, sadly enough, not all types of blood 
cancers are provided with such therapeutic options. Besides that, in 
the course of treatment, some leukemias develop resistance even to 
targeted drugs and disease relapses with more aggressive pheno-
types being refractory to multiple other chemotherapeutic drugs. 
These undesired outcomes make researchers look for new therapies 
overcoming the caveats of the current options. Sphingolipid  
metabolism appears to be a good target for that purpose. This  
section of the article is concentrated on possible applications of this  
approach for the treatment of leukemias. 
 Acute lymphoblastic leukemia (ALL) occurs mainly at child-
hood with unknown direct causative factors. However some genetic 
changes altering the expressions of hematopoietic transcription 
factors are suspected to be responsible for the malignant transfor-
mation [164] (for more detailed information about characteristics of 
ALL, please see reviews [165] and [166]). A recent report showed 
that membrane-bound sialidase, an enzyme responsible for the deg-
radation of gangliosides, was downregulated in ALL; and when 
sialidase was overexpressed, apoptotic induction was obtained with 
the concomitant increase in ceramide levels and decrease in lacto-
sylceramide [167]. By another report, ganglioside GD3 was found 
to be upregulated [168] and O-acetylated in ALL cells rendering it 
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unable to induce apoptosis suggesting that it is a survival trick 
adopted by leukemic cells [169]. As mentioned briefly in the previ-
ous sections, retinoid 4-HPR causes elevation of ceramide levels 
and induces apoptosis. This induction was shown to be malignancy-
specific for ALL cells as evidenced by increased cytotoxicity in 
leukemic cells whereas non-transformed cells were unaffected 
[170]. Taken together, those data indicate interventions increasing 
cellular ceramide levels might be a promising approach for effec-
tive ALL therapies. Gangliosides such as GD3 might have impor-
tant implications for the development of immunotherapy to ALL on 
the other hand. In this approach, highly upregulated gangliosides  
on the cell surface could be used as markers of malignant cells. 
Another study showed that significant amounts of antibody-
dependent cellular cytotoxicity could be obtained in serum when 
ALL cells are treated with monoclonal antibodies recognizing GD3 
[171]. In addition to this, CD1d-bearing ALL subsets are known to 
present -galactosylceramide to CD1d-restricted T-cells [172]. 
Even though this event was shown as a poor prognostic marker, it 
may lead to new immunotherapeutic interventions. For instance, -
galactosylceramide-pulsed antigen presenting cells and in vitro
expanded natural killer T cells (NKT cells) were shown to be  
effective for immunotherapeutic clearance of solid tumors when 
delivered to tumor microenvironment [173-175]. While not all -
galactosylceramide analogs are effective in the same manner [176, 
177], KRN7000 in particular, was shown to stimulate invariant 
natural killer T cells (iNKT cells) and evoke an immune response 
against viruses and tumors [178-180]. Because of its potential,  
there has been phase-I and phase-II trials assessing the efficacy of 
KRN7000 in various solid tumors and myelomas (with the identifiers 
of NCT00003985 and NCT00698776 respectively) [181-185].  
 Acute myeloid leukemia (AML) originates from myeloid line-
age unlike ALL. Radiation and chemotherapy are among the causa-
tive factors identified so far [186]. Ceramide appears to be impor-
tant in the chemotherapeutic cytotoxicity for AML cells as well 
[187, 188]. Studies with AML cells showed that ceramides might 
be important for heat-shock induced apoptosis [189]. Immunologic 
clearance of leukemic cells by TRAIL-induced apoptosis was ob-
served after pulsing dendritic cells with -galactosylceramide but 
not prior to pulsing, suggesting that other sphingolipids might have 
roles for other effective therapeutic approaches [190]. Interestingly, 
ceramides were shown to be potent to induce differentiation in 
AML cells which somewhat show the characteristics of immature 
stem cells [131, 191]. Some gangliosides, neolacto-series and GM3 
in particular, have similar roles for the differentiation of leukemic 
cells [192, 193]. P-glycoprotein, P-gp, (protein product of multi 
drug resistance 1 gene, MDR1) is responsible for the drug resis-
tance developed by different types of blood cancers including 
AML. P-gp was shown to induce conversion of ceramide to GluCer 
allowing cancer cell survival in addition to its direct drug-efflux 
functions [194, 195]. Overexpression of sphingosine kinase which 
is responsible for the production of proliferative S1P was shown  
to cause MDR1-associated chemotherapeutic resistance in AML 
cell lines [196]. This observation was supported by other papers 
indicating that S1P upregulation is an important oncogenic 
achievement in the cancer progression producing refractory sub-
types [197]. In the light of the data attributing essential roles to 
sphingolipids in the leukomogenesis and drug resistance, targeting 
sphingosine kinase pathway might be a promising approach to 
overcome chemoresistance for AML in particular. 
 Chronic lymphocytic leukemia (CLL) is the most common form 
of leukemia and it is characterized by elevated levels of immature 
white blood cells in bloodstream similarly to other leukemias, but 
CD5-positive B cells being in particular for this case. Various stud-
ies have shown that CLL is manifested by the lack of apoptosis as 
evidenced by accumulation of G0 quiescent cells [198]. Therefore 
re-activation of apoptotic pathway might be an effective approach 
to eradicate CLL. One aggressive form of this leukemia was shown 
to be efficiently eradicated and complete remission was obtained in 
rats through the delivery of liposomal short chain ceramides that 
target survivin pathway [199]. Besides this, lipid rafts and particular 
gangliosides are thought to have implications for obtaining better 
clearance of leukemic cells. GM1 and GM3 were found to be ele-
vated in B-cell neoplasms as evidenced by various biochemical 
assessments [200, 201]. Even though studies making this discovery 
couldn’t provide a satisfying explanation about their specific roles 
in malignancy, those sphingolipid species may have importance as 
diagnostic and therapeutic markers. Alemtuzumab, an antibody 
recognizing CD52 membrane proteins for immunotherapy, was 
shown to induce caspase-dependent cell death through lipid rafts 
which are rich in GM1 ganglioside [202]. Similar to ALL cases 
mentioned above, CD1d marker is also expressed on CLL cells and 
functions as -galactosylceramide presenting protein which may 
lead to development of novel immunotherapies to CLL through a 
similar approach that targets CD1d [203]. 
 Chronic myeloid leukemia (CML) is maybe the most well-
characterized leukemia type among others. A reciprocal transloca-
tion between chromosomes 9 and 22 is the driving force of malig-
nant transformation in majority of the CML cases. That transloca-
tion results in the production of a fusion protein called BCR-ABL 
which shows constitutive tyrosine kinase activity in the cells [204]. 
BCR-ABL phosphorylates key proteins which in turn initiate pro-
liferation and cell division. CML is the first leukemia type to which 
targeted chemotherapies are developed. There are drugs specifically 
binding to the fusion protein and blocking its kinase activity yield-
ing reduction of leukemic cells in bloodstream to almost undetect-
able levels [205, 206]. Similar to what is seen above; ceramides are 
thought to be important mediators of apoptosis in CML cells, and 
the delicate balance in sphingolipid rheostat was shown to be im-
portant for chemoresistance [207]. BCR-ABL might be competing 
with ceramides for providing survival abilities to leukemic cells as 
shown by a study indicating Abl kinase as a negative regulator of 
Fas-mediated cell death which is a convergent pathway for cera-
mide signaling [208, 209]. In addition to the importance of cera-
mides, some gangliosides (GM3 in particular here as well) were 
shown to be potent for inducing megakaryocytic differentiation of 
CML blasts [210, 211]. Moreover, desialylation of some glycopro-
teins by Neu2, a cytosolic sialidase, might block BCR-ABL/Src 
signaling [212]. Another report might be providing supportive evi-
dence for such convergent mechanisms by showing that BCR-ABL 
regulates membrane GM1 levels and expression of ligands for natu-
ral killer cell receptors [213]. In this study, treatment of BCR-ABL 
positive cells with imatinib, a specific tyrosine kinase inhibitor, 
modulated levels of those molecules indicating that BCR-ABL  
is the actual factor responsible for this regulation. Some surface 
glycosphingolipids such as fucosylated gangliosides were shown  
as possible targets for immunotherapeutic interventions for CML 
since they may participate into the antigen presentation processes 
[214, 215]. 
CONCLUSION AND FUTURE PERSPECTIVES 
 Regulation of cell death and survival is a complex process in-
volving numerous pathways and dozens of proteins. Accumulated 
scientific knowledge so far attributed new roles to sphingolipids in 
this regulation besides their structural roles in membranes. In-
volvement of sphingolipids in these mechanisms appears to be not 
less important than previously known proteins and other small sig-
naling molecules. In fact, deregulation of sphingolipid metabolism 
is now known as the causative factors for several diseases including 
but not limited to metabolic disorders and cancer. Moreover, with 
each study completed, scientists are discovering that sphingolipids 
are important mediators for mechanisms of action of several drugs, 
adding more importance to sphingolipids for the development of 
better therapeutic options, especially in the cancer area. Numerous 
reports have shown that altered ceramide metabolism upon chemo-
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therapy is a major contributor to the cytotoxicity [216-218]. These 
experiments showed that inhibition of enzymes responsible for the 
production of apoptotic sphingolipid species (or in some cases 
overexpression of opposing enzymes) abrogates the cytotoxicity of 
the drug, and conversely overexpression of the same enzymes cor-
related with increased chemotherapeutic sensitivity suggesting that 
certain sphingolipid species are important for cytotoxicity of the 
drug [219-221]. Some other studies have also shown that therapeu-
tic efficacy of cancer drugs can be significantly enhanced in combi-
nation with growth-suppressive sphingolipids such as ceramides 
and sphingosine [222-224]. Therefore, manipulation of sphingolipid 
metabolism comes forward as a good intervention approach for 
novel therapies [225]. Importance of some sphingolipid species in 
chemotherapeutic response and upregulation of proliferative types 
in the case of drug resistance make researchers think that che-
motherapeutic outcome can be improved significantly through alter-
ing sphingolipid metabolism. This approach provides an exciting 
hot topic for the development of better therapeutics in the future (as 
reviewed in [226] and [35]). Acute and chronic leukemias are 
among the cancer types upon which we built majority of our 
knowledge about the involvement of sphingolipids in cancer thera-
peutics. Hence, leukemias might be good starting points for incor-
poration of sphingolipids for new treatments. Specificity of some 
sphingolipid species for malignant cells makes this approach feasi-
ble and exciting enough to pursue. However, for applying sphin-
golipid based therapeutics to several other types of leukemias and 
cancers, we may need to develop ways to deliver cytotoxic species 
specifically to the malignant cells. By this way, this approach might 
be generalized for other types of cancers as well to obtain enhanced 
eradication of the malignant cells. In the light of the accumulating 
literature in this area, it is suffice to say that sphingolipid metabo-
lism holds a significant importance for the future therapeutics of 
various cancers and shows promise for better results in clinic that 
would bring us closer to the ultimate aim: changing the nature of 
cancer from being deadly in many cases, to being curable. 
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